The global bleeding disorder testing market is expected to garner a market value of US$ 95 Billion in 2023 and is expected to accumulate a market value of US$ 190 Billion by registering a CAGR of 7.2% in the forecast period 2023 to 2033. The rising prevalence of various types of bleeding disorders such as Von Willebrand disease, haemophilia A, haemophilia B, and others are driving the bleeding disorder testing market growth.
A clump of platelets and a specific type of blood cell develops in the affected bodily area. This clot keeps pathogens out of the blood and keeps blood from draining from the wounded region. Bleeding disorder testing can help identify whether particular clotting factors are present and how long it takes for blood to clot.
The test determines how long it takes for the arteries to constrict and for platelets in the blood to shut off the opening. Von Willebrand disease is the most prevalent bleeding ailment, affecting around 1 in every 100 persons, or up to 1% of the USA population, as stated by the National Hemophilia Foundation.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 95 Billion |
| Anticipated Forecast Value (2033) | US$ 190 Billion |
| Projected Growth Rate (2023 to 2033) | 7.2% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for bleeding disorder testing is projected to increase at a CAGR of 7.2% during the forecast period between 2023 and 2033, reaching a total of US$ 195 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 6%.
The increased frequency of bleeding disorders among the general population, as well as the growing elderly population, which is more vulnerable to certain medical diseases, are among the primary drivers driving the global market. Additionally, the increasing acceptance of health insurance policies that give financial support for bleeding disorder treatment bleeding, testing, and lower healthcare costs is favorably affecting the market.
Increasing Prevalence of Blood Disorders to Improve Maintenance and Performance
Blood problems are a type of chronic sickness. They are also dangerous since they circulate throughout the blood. Disorders such as liver disease, anaemia, and other blood coagulation issues have grown, as has the need for bleeding disorders testing. These hereditary illnesses resulted in profitable market expansion.
Investments by the Government in Healthcare Interoperability Influencing the Market
The federal government's increased financing to drive the adoption of these solutions has an additional impact on the industry. Furthermore, the increase in healthcare spending, developments in healthcare infrastructure, and increasing demand for extended care delivery all have a beneficial impact on the bleeding disorders testing industry, supporting market expansion.
Principal Consultant
A Scarcity of Qualified Professionals to be a Major Obstacle for the Market Growth
The shortage of qualified experts and talented professionals would be a significant hindrance to the expansion of the bleeding disorders testing market. Medication prices will also hinder market expansion.
Inadequate reimbursement policies will limit the breadth as well. Unprofessional therapies can have serious consequences for the patient's health. This difficulty is impeding market expansion.
Low adherence to regulations to Impede Market Growth
The lack of attention of national organizations and other institutions in developing nations on raising awareness about these illnesses results in limited penetration of testing. This problem is impeding market expansion by preventing early diagnosis and effective patient care.
Government’s Initiative for Better Healthcare Infrastructure Widening Profit Margins
As a consequence of greater knowledge of bleeding disorders and treatment alternatives, Asia-Pacific is likely to see a significant CAGR in the future years, boosting the worldwide bleeding disorder testing market.
Furthermore, the government's push to develop healthcare infrastructure benefits the expansion of the bleeding disease testing business. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 6.5% in the assessment period 2023 to 2033.
Increased Availability of Testing Devices to Push Market Sales in the Region
North America is expected to have the highest CAGR over the projection period, owing to the increase that can be attributed to the increased availability of bleeding disorder testing instruments and the rising number of regulatory approvals.
The rising awareness about the bleeding disorders symptoms and diagnosis rate of bleeding disorders is expected to drive market expansion. North America is expected to grow at a CAGR of 7.1% in the assessment period 2023 to 2033.
Increasing Frequency of Disorders in the Region fuelling Sales
The increasing frequency of bleeding disorders in Germany, the United Kingdom, and other nations is expected to drive the Europe bleeding disorder testing market share. The expanding patient population and rising adherence to recommendations boosted demand.
The testing tools and technologies in this region are quite advanced, which has increased the market share. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 6.9% in the forecast period 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Reagents and Consumables segment will see Profitable Growth
The market is divided into two categories: reagents & consumables and instruments. Given the skyrocketing frequency of testing driven by healthcare access in emerging nations, the reagents and consumables industry is expected to rise significantly.
The Hemophilia A Segment share will Increase
The bleeding disorder testing market is divided into haemophilia A, haemophilia B, Von Willebrand disease, idiopathic thrombocytopenic purpura, and others. Over the projection period, the haemophilia A sector is expected to increase significantly. The increase can be attributed to the rising prevalence of bleeding disorders.
The Diagnostic Centers Segment will see a Commendable Increase
The market is split into hospitals & clinics, diagnostic centers, and others based on end-user. Over the forecast period, the diagnostic center's segment is expected to increase significantly. The rise can be attributed to an increase in the number of portable analyzers and rapid technological developments.
Key start-up players in the bleeding disorder testing are:
Prominent bleeding disease testing organizations are focusing on strategic strategies such as alliance development, acquisitions, mergers, and others. These actions are being done to strengthen the market position. Increasing involvement in trade shows is one of the extra strategies. Key players in the bleeding disorder testing market are Sysmex Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., HORIBA Ltd., and Abbott, Thermo Fisher Scientific Inc.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 95 Billion |
| Market Value in 2033 | US$ 190 Billion |
| Growth Rate | CAGR of 7.2% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global bleeding disorder testing market to expand at a 7.2% value CAGR by 2033
The global bleeding disorder testing market is estimated at a market value of US$ 95 Billion
The global bleeding disorder testing market is expected to garner a market value of US$ 190 Billion
North America is forecast to be the most lucrative for bleeding disorder testing market growth.
Sysmex Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., HORIBA Ltd., Abbott, and Thermo Fisher Scientific Inc. are some prominent bleeding disorder testing manufacturers
As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 6.5% in the assessment period 2023 to 2033.
Europe is expected to grow at a CAGR of 6.9% in the forecast period 2023 to 2033.
The diagnostic center's segment is expected to hold the largest market share for bleeding disorder testing in the forecast period 2023 to 2033.
1. Executive Summary | Bleeding Disorder Testing Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033
5.3.1. Reagents & Consumables
5.3.2. Instruments
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
6.3.1. Hemophilia A
6.3.2. Hemophilia B
6.3.3. Von Willebrand Disease
6.3.4. Idiopathic Thrombocytopenic Purpura
6.3.5. Other Indications
6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospitals & Clinics
7.3.2. Diagnostic Centres
7.3.3. Other
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia & Pacific
8.3.5. East Asia
8.3.6. Middle East and Africa(MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Product Type
9.2.3. By Indication
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By Indication
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Product Type
10.2.3. By Indication
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Indication
10.3.4. By End User
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Product Type
11.2.3. By Indication
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Indication
11.3.4. By End User
11.4. Key Takeaways
12. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Australia
12.2.1.6. New Zealand
12.2.1.7. Rest of South Asia & Pacific
12.2.2. By Product Type
12.2.3. By Indication
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Indication
12.3.4. By End User
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Product Type
13.2.3. By Indication
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Indication
13.3.4. By End User
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of Middle East and Africa(MEA)
14.2.2. By Product Type
14.2.3. By Indication
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Type
14.3.3. By Indication
14.3.4. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Product Type
15.1.2.2. By Indication
15.1.2.3. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Product Type
15.2.2.2. By Indication
15.2.2.3. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Product Type
15.3.2.2. By Indication
15.3.2.3. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Product Type
15.4.2.2. By Indication
15.4.2.3. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Product Type
15.5.2.2. By Indication
15.5.2.3. By End User
15.6. United Kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Product Type
15.6.2.2. By Indication
15.6.2.3. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Product Type
15.7.2.2. By Indication
15.7.2.3. By End User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Product Type
15.8.2.2. By Indication
15.8.2.3. By End User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Product Type
15.9.2.2. By Indication
15.9.2.3. By End User
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Product Type
15.10.2.2. By Indication
15.10.2.3. By End User
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Product Type
15.11.2.2. By Indication
15.11.2.3. By End User
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Product Type
15.12.2.2. By Indication
15.12.2.3. By End User
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Product Type
15.13.2.2. By Indication
15.13.2.3. By End User
15.14. China
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Product Type
15.14.2.2. By Indication
15.14.2.3. By End User
15.15. Japan
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Product Type
15.15.2.2. By Indication
15.15.2.3. By End User
15.16. South Korea
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Product Type
15.16.2.2. By Indication
15.16.2.3. By End User
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Product Type
15.17.2.2. By Indication
15.17.2.3. By End User
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Product Type
15.18.2.2. By Indication
15.18.2.3. By End User
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Product Type
15.19.2.2. By Indication
15.19.2.3. By End User
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Product Type
15.20.2.2. By Indication
15.20.2.3. By End User
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Product Type
15.21.2.2. By Indication
15.21.2.3. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Product Type
16.3.3. By Indication
16.3.4. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Siemens Healthcare GmbH
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. F. Hoffman-La Roche Ltd.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Thermo Fisher Scientific Inc.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Abbot Laboratories
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Atlas Medical GmbH
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Horiba Ltd
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Hyphen Bio Med
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Precision Biologics Incorporated
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Pfizer Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Baxter
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Bleeding Disorder Testing Market
